,Description,Variations,ClinVar,Frequency,Studies,Risk
rs1815739,muscle performance,"[['(C;C)', '2.2', 'Better performing muscles. Likely sprinter.'], ['(C;T)', '2.1', 'Mix of muscle types. Likely sprinter.'], ['(T;T)', '2.2', 'Impaired muscle performance. Likely endurance athlete.']]","['Benign', 'ACTN3 deficiency', 'Affects', 'Sprinting performance', 'Pathogenic']","
                  T=0.46138
                  (114812/248844, GnomAD_exome)
                ",Cellular Aspects of Muscle Specialization Demonstrate Genotype – Phenotype Interaction Effects in Athletes,C>T
rs53576,influences social behavior and personality,"[['(A;A)', '2.8', 'Lack of empathy?'], ['(A;G)', '2.8', 'Lack of empathy?'], ['(G;G)', '2.5', 'Optimistic and empathetic; handle stress well']]",[],"
                  A=0.31514
                  (39572/125568, TOPMED)
                ",The oxytocin receptor gene predicts brain activity during an emotion recognition task in autism,A>G / A>T
rs4680,warrior vs worrier; number of other associations,"[['(A;A)', '2.5', '(worrier) advantage in memory and attention tasks'], ['(A;G)', 'Intermediate dopamine levels, other effects'], ['(G;G)', '2.5', '(warrior) multiple associations, see details']]","['Benign', 'nicotine response - Efficacy', 'Drug-Response', 'not specified', 'Benign', 'tramadol response - Dosage, Efficacy', 'Drug-Response', 'methadone response - Dosage, Efficacy', 'Drug-Response', 'morphine response - Dosage, Efficacy', 'Drug-Response', 'opioids response - Dosage, Efficacy', 'Drug-Response', 'oxycodone response - Dosage, Efficacy', 'Drug-Response', 'remifentanil response - Dosage, Efficacy', 'Drug-Response', 'sufentanil response - Dosage, Efficacy', 'Drug-Response']","
                  A=0.46109
                  (114049/247346, GnomAD_exome)
                ",A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers,G>A
rs1800497,,"[['(C;C)', '3', 'Normal (A2/A2)'], ['(C;T)', '2.9', 'A1/A2: Bad at avoidance of errors. 0.5x lower OCD risk, 0.87x lower Tardive Diskinesia risk, higher ADHD risk. More Alcohol Dependence. Lower risk of Postoperative Nausea. Increased obesity. Bupropion is not effective for smoking cessation.'], ['(T;T)', '4', 'A1/A1: Bad at avoidance of errors. 0.25x lower OCD; 0.56x lower Tardive Diskinesia; higher ADHD; 1.4x Alcohol Dependence; lower Postoperative Nausea; Increased obesity; less pleasure response; Bupropion ineffective for smoking cessation.; 2.4x risk for adenoma recurrence.']]","['Benign', 'ethanol response - Toxicity/ADR', 'Drug-Response', 'clozapine response - Toxicity/ADR', 'Drug-Response', 'bupropion response - Efficacy', 'Drug-Response', 'olanzapine response - Toxicity/ADR', 'Drug-Response', 'antipsychotics response - Toxicity/ADR', 'Drug-Response', 'risperidone response - Toxicity/ADR', 'Drug-Response', 'not specified', 'Benign']","
                  A=0.26419
                  (65225/246888, GnomAD_exome)
                ",DRD2/ANKK1 Polymorphism Modulates the Effect of Ventral Striatal Activation on Working Memory Performance,G>A
rs429358,,"[['(C;C)', '1.2', 'one of 2 snps relevant to classifying APOE genotype'], ['(C;T)', "">3x increased risk for Alzheimer's; 1.4x increased risk for heart disease""], ['(T;T)', '0', 'common']]","['Pathogenic', 'Alzheimer disease 2', 'Pathogenic', 'Familial type 3 hyperlipoproteinemia', 'Pathogenic', 'APOE4(-)-FREIBURG', 'Pathogenic', 'APOE4 VARIANT', 'Association', 'not provided', 'Other']","
                  C=0.13850
                  (23502/169692, GnomAD_exome)
                ",Apolipoprotein E polymorphisms increase the risk of post-stroke depression,T>C
rs9939609,Obesity related. Raises T2D risk through obesity.,"[['(A;A)', '3', 'obesity risk and 1.6x risk for T2D'], ['(A;T)', '2.4', '1.3x risk for T2D; obesity risk'], ['(T;T)', '1.5', 'lower risk of obesity and Type-2 diabetes']]",[],"
                  A=0.40273
                  (50570/125568, TOPMED)
                ",,T>A
rs4988235,,"[['(C;C)', '2.5', 'likely to be lactose intolerant as an adult'], ['(C;T)', '1.1', 'likely to be able to digest milk as an adult'], ['(T;T)', '1.1', 'can digest milk']]",['Association'],"
                  A=0.38766
                  (48678/125568, TOPMED)
                ","Dairy consumption, systolic blood pressure, and risk of hypertension: Mendelian randomization study",G>A / G>C
rs6806903,,[],[],"
                  G=0.27626
                  (34689/125568, TOPMED)
                ",,A>G
rs4244285,Clopidogrel (Plavix®),"[['(A;A)', '4', 'poor metabolizer of several popular medicines; patients prescribed Plavix get less benefit, and have higher risk for adverse cardiovascular events'], ['(A;G)', '3', 'poorer metabolizer of several popular medicines; patients prescribed Plavix get less benefit, and have higher risk for adverse cardiovascular events'], ['(G;G)', '0', 'normal']]","['Drug-Response', 'Proguanil, poor metabolism of', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'amitriptyline response - Efficacy', 'Drug-Response', 'clopidogrel response - Efficacy, Toxicity/ADR', 'Drug-Response', 'citalopram response - Efficacy', 'Drug-Response', 'clomipramine response - Efficacy', 'Drug-Response', 'not provided', 'Other', 'not specified', 'Likely-Benign', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'CYP2C19: no function', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Clopidogrel response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Citalopram response', 'Drug-Response', 'Escitalopram response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Sertraline response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response', 'Voriconazole response', 'Drug-Response']","
                  A=0.17640
                  (28518/161670, GnomAD_exome)
                ",Genetic Polymorphisms of Metabolic Enzymes and the Pharmacokinetics of Indapamide in Taiwanese Subjects,G>A / G>C
rs1801133,Folic acid processing; homocysteine levels,"[['(C;C)', '0', 'Common genotype: normal homocysteine levels'], ['(C;T)', '2.2', '1 copy of C677T allele of MTHFR = 65% efficiency in processing folic acid'], ['(T;T)', '2.8', 'homozygous for C677T of MTHFR = 10-20% efficiency in processing folic acid = high homocysteine, low B12 and folate levels']]","['Conflicting-Interpretations-Of-Pathogenicity', 'Gastrointestinal stroma tumor', 'Uncertain-Significance', 'not provided', 'Uncertain-Significance,Other', 'cyclophosphamide response - Toxicity/ADR', 'Drug-Response', 'carboplatin response - Efficacy', 'Drug-Response', 'Neural tube defects, folate-sensitive', 'Likely-Benign', 'methotrexate response - Dosage, Efficacy, Toxicity/ADR', 'Drug-Response', 'Neoplasm of stomach', 'Not-Provided', 'not specified', 'Benign', 'Venous thrombosis', 'Uncertain-Significance']","
                  A=0.31486
                  (79177/251468, GnomAD_exome)
                ","Methylenetetrahydrofolate reductase tagging polymorphisms are associated with risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 Chinese Han subjects",G>A
rs9378252,,"[['(A;A)', '0', 'common in clinvar'], ['(A;T)', '1', 'benign'], ['(T;T)', '1', 'benign']]","['Pathogenic', 'not specified', 'Benign']","
                  T=0.04407
                  (7165/162570, GnomAD_exome)
                ",,A>G / A>T
rs204890,,"[['(G;G)', '0', 'common in complete genomics']]",[],"
                  T=0.02968
                  (5218/175784, GnomAD_exome)
                ",MHC region and risk of systemic lupus erythematosus in African-American women,C>T
rs6472,,"[['(C;C)', '0', 'benign polymorphism'], ['(C;G)', '0', 'benign polymorphism'], ['(G;G)', '0', 'common/normal']]","['Benign', 'Congenital adrenal hyperplasia', 'Not-Provided', 'Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'Benign', 'not specified', 'Benign']","
                  C=0.1238
                  (3811/30776, GnomAD)
                ",,G>A / G>C
rs6410,,"[['(A;A)', '0', 'common in clinvar']]","['Benign', 'Hyperaldosteronism, familial, type I', 'Benign']","
                  T=0.41910
                  (105248/251126, GnomAD_exome)
                ",,T>A / T>C
rs2486758,,"[['(C;C)', '2.2', 'Slightly higher prostate cancer risk; poorer response to AA/P treatment'], ['(C;T)', '2', 'Slightly higher prostate cancer risk; poorer response to AA/P treatment'], ['(T;T)', '2', 'Slightly lower prostate cancer risk; better response to AA/P treatment']]",[],"
                  C=0.17057
                  (21418/125568, TOPMED)
                ",Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population,T>C
rs2296239,,"[['(C;C)', '0', 'common in clinvar']]",['Benign'],"
                  T=0.27941
                  (70250/251420, GnomAD_exome)
                ",Genetic association analysis of vitamin D pathway with obesity traits,C>T
rs11621961,,[],[],"
                  T=0.30322
                  (38075/125568, TOPMED)
                ","Investigation of Genetic Variants, Birthweight and Hypothalamic-Pituitary-Adrenal Axis Function Suggests a Genetic Variant in the SERPINA6 Gene Is Associated with Corticosteroid Binding Globulin in the Western Australia Pregnancy Cohort (Raine) Study",C>T
rs1009382,,[],['Benign'],"
                  C=0.28018
                  (67520/240990, GnomAD_exome)
                ",High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions,C>A / C>G / C>T
rs1134095,,[],"['Benign', 'Congenital adrenal hyperplasia', 'Benign']","
                  G=0.38656
                  (48540/125568, TOPMED)
                ",,G>A
rs6387,,"[['(G;G)', '0', 'common in clinvar']]","['Benign', 'Hyperaldosteronism, familial, type I', 'Benign']","
                  C=0.49504
                  (62161/125568, TOPMED)
                ",,C>G / C>T
rs284849,,[],[],"
                  T=0.14747
                  (18517/125568, TOPMED)
                ",,G>T
rs1269851,,[],[],"
                  C=0.05702
                  (7160/125568, TOPMED)
                ",,T>C
rs4539,,"[['(A;A)', '0', 'common in clinvar']]","['Benign', 'Hyperaldosteronism, familial, type I', 'Benign', 'Corticosterone methyloxidase type 2 deficiency', 'Benign', 'not specified', 'Benign']","
                  C=0.42399
                  (105290/248332, GnomAD_exome)
                ",Association between Polymorphisms in the Renin-Angiotensin-Aldosterone System Genes and Essential Hypertension in the Han Chinese Population,T>C
rs1134096,,[],"['Benign', 'Hyperaldosteronism, familial, type I', 'Benign']","
                  C=0.38656
                  (48539/125568, TOPMED)
                ",,C>A
rs1269854,,[],[],"
                  C=0.06094
                  (7652/125568, TOPMED)
                ",,T>C
rs9267798,,[],[],"
                  C=0.08506
                  (10681/125568, TOPMED)
                ",,G>C
rs204894,,[],[],"
                  A=0.03500
                  (8803/251486, GnomAD_exome)
                ",,G>A
rs915908,,"[['(G;G)', '0', 'common in complete genomics']]",[],"
                  A=0.12611
                  (15836/125568, TOPMED)
                ",Assessment of interaction between maternal polycyclic aromatic hydrocarbons exposure and genetic polymorphisms on the risk of congenital heart diseases,G>A
rs204999,,[],[],"
                  G=0.29457
                  (36988/125568, TOPMED)
                ",A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32,A>G
rs204887,,[],['Benign'],"
                  A=0.36781
                  (46185/125568, TOPMED)
                ",,A>G / A>T
rs12530380,,"[['(A;A)', '3', 'Miscall likely if from 23andMe user data'], ['(T;T)', '0', 'common in clinvar']]","['Pathogenic', 'Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'Pathogenic']",-,,T>A
rs4998896,,[],[],"
                  A=0.00000
                  (1/251472, GnomAD_exome)
                ",,C>A / C>T
rs743572,,"[['(A;A)', '0', 'common in clinvar']]",['Benign'],"
                  G=0.39840
                  (50026/125568, TOPMED)
                ",Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness,A>G / A>T
rs6405,,[],[],"
                  T=0.00015
                  (37/250968, GnomAD_exome)
                ",,C>T
rs1137486,,[],[],-,,C>A / C>T
rs5292,,[],[],None,,G>C
rs35045158,,[],[],"
                  A=0.02155
                  (2706/125568, TOPMED)
                ",,G>A
rs1042854,,[],[],None,,G>T
rs5301,,[],"['Benign', 'Hyperaldosteronism, familial, type I', 'Benign']","
                  C=0.48152
                  (60464/125568, TOPMED)
                ",,T>C
rs5297,,[],"['Benign', 'Congenital adrenal hyperplasia', 'Benign']","
                  G=0.13214
                  (16592/125568, TOPMED)
                ",Linking Genomic and Metabolomic Natural Variation Uncovers Nematode Pheromone Biosynthesis,A>G
rs7003319,,[],"['Benign', 'Hyperaldosteronism, familial, type I', 'Benign']","
                  T=0.38656
                  (48539/125568, TOPMED)
                ",,T>C
rs4534,,[],"['Benign', 'Congenital adrenal hyperplasia', 'Benign']","
                  T=0.08449
                  (21242/251402, GnomAD_exome)
                ",Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects,C>T
rs1137485,,[],[],"
                  G=0.00002
                  (2/125568, TOPMED)
                ",,C>G
rs1137483,,[],[],-,,T>C
rs28934586,,"[['(A;G)', '3', 'Carrier of a congenital adrenal hyperplasia mutation'], ['(G;G)', '0', 'common in clinvar']]",['Likely-Pathogenic'],"
                  T=0.00002
                  (6/251406, GnomAD_exome)
                ",,C>T
rs17115100,,"[['(G;G)', '0', 'common on affy axiom data'], ['(G;T)', '1.5', ""slightly increased risk of developing Parkinson's Disease""], ['(T;T)', '2', ""Increased risk of developing Parkinson's Disease""]]",[],"
                  T=0.14254
                  (35549/249388, GnomAD_exome)
                ",Novel disease syndromes unveiled by integrative multiscale network analysis of diseases sharing molecular effectors and comorbidities,G>T
rs6162,,"[['(G;G)', '0', 'common in clinvar']]","['Benign', 'not provided', 'Benign']","
                  A=0.42336
                  (106461/251466, GnomAD_exome)
                ",Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness,G>A
rs6163,,[],"['Benign', 'not provided', 'Benign']","
                  A=0.39797
                  (49972/125568, TOPMED)
                ",Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness,C>A / C>T
rs1004467,,"[['(T;T)', '0']]",[],"
                  G=0.15280
                  (38333/250872, GnomAD_exome)
                ",A Study on the Association Between Polymorphisms in the Cytochrome P450 Family 17 Subfamily A Member 1 Gene Region and Type 2 Diabetes Mellitus in Han Chinese,A>G
rs6445,,"[['(C;C)', '0', 'common in complete genomics'], ['(C;T)', '3', 'Carrier of allele for congenital adrenal hyperplasia'], ['(T;T)', '5', 'Congenital adrenal hyperplasia']]","['Pathogenic', 'not provided', 'Pathogenic']","
                  T=0.00460
                  (633/137706, GnomAD_exome)
                ",,C>T
